Article Versions Notes

Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, et al. A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers. 2021; 13(10):2466. https://doi.org/10.3390/cancers13102466

Atkinson, Victoria G., Pietro Quaglino, Massimo Aglietta, Michele Del Vecchio, Roberta Depenni, Francesca Consoli, Dimitrios Bafaloukos, Pier Francesco Ferrucci, Skaiste Tulyte, Ivana Krajsová, and et al. 2021. "A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)" Cancers 13, no. 10: 2466. https://doi.org/10.3390/cancers13102466

Atkinson, V. G., Quaglino, P., Aglietta, M., Del Vecchio, M., Depenni, R., Consoli, F., Bafaloukos, D., Ferrucci, P. F., Tulyte, S., Krajsová, I., Ascierto, P. A., Gueli, R., Arance, A., Gogas, H., Banerjee, H., Saliba, T., de Jong, E., & Neyns, B. (2021). A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 13(10), 2466. https://doi.org/10.3390/cancers13102466